Want to see LGVN full AI Analyst Report?
Top Page
Longeveron
(NASDAQ:LGVN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$6.50
▲(855.88% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance—persistent large losses, heavy cash burn, and limited runway—alongside soft technicals with the stock trading below key moving averages. These are partially offset by a defined near-term clinical catalyst and validation milestones from the latest earnings call, plus generally positive governance/leadership events.
Positive Factors
Regulatory and intellectual-property support
The broad patent estate and expedited FDA designations can protect differentiation, support faster regulatory engagement and improve partnering prospects across multiple high-need regenerative medicine indications.
Negative Factors
Persistent cash burn and limited runway
Sustained cash consumption means Longeveron must secure financing, partnerships or other capital to continue development. This creates ongoing funding risk and could constrain trial execution or commercialization investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory and intellectual-property support
The broad patent estate and expedited FDA designations can protect differentiation, support faster regulatory engagement and improve partnering prospects across multiple high-need regenerative medicine indications.
Read all positive factors
Longeveron Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how Longeveron’s revenue is split across sources such as clinical trial services, grants, collaboration or licensing payments, and any product or service sales. A mix weighted toward grants and milestone payments means revenue can be lumpy and dependent on partnership timing; growing product or recurring revenue would indicate progress toward commercialization, steadier cash flow, and lower execution risk for investors.
Shows how Longeveron’s revenue is split across sources such as clinical trial services, grants, collaboration or licensing payments, and any product or service sales. A mix weighted toward grants and milestone payments means revenue can be lumpy and dependent on partnership timing; growing product or recurring revenue would indicate progress toward commercialization, steadier cash flow, and lower execution risk for investors.
Data provided by:
The Fly
The FlyLongeveron (LGVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.87M
Dividend YieldN/A
Average Volume (3M)62.75K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue Growth-42.74%
EPS Growth20.66%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.10
Shares Outstanding3,043,297
10 Day Avg. Volume79,027
30 Day Avg. Volume62,748
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.2
Revenue Forecast (FY)$1.54M
Longeveron Business Overview & Revenue Model
Company Description
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illne...
How the Company Makes Money
Longeveron does not have a widely documented, recurring commercial product revenue stream; null. As a clinical-stage biotech, its financial inflows have primarily come from financing activities (e.g., issuing equity/other securities) and, where ap...
Longeveron Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 06, 2026
Earnings Call Sentiment Neutral
The call balanced meaningful scientific, regulatory, and validation milestones (upcoming ELPIS II readout, XPRIZE finalist award, high-profile publications, strong IP and expedited designations, and regulatory progress for PDCM) against material financial constraints (very low revenues, rising expenses, widening net loss, and a cash runway into Q4 2026). The business outlook is highly dependent on the imminent trial readout and the company's ability to secure partnerships or financing to extend the runway and commercialize programs.Positive Updates
Near-term ELPIS II Top-line Data Readout
Top-line results from the Phase 2b ELPIS II trial in hypoplastic left heart syndrome (HLHS) are expected in mid-September following a planned database lock on August 31. Management emphasized FDA engagement and alignment on endpoints/SAP, and indicated a potential BLA pathway if data are supportive.
Negative Updates
Very Low Quarterly Revenues and Year-over-Year Decline
Total revenue for the quarter was $0.3 million, a decrease of $29 thousand or 10% versus the prior-year period, primarily due to the absence of contract manufacturing revenue.
Read all updates
Q2-2026 Updates
Positive
Negative
Near-term ELPIS II Top-line Data Readout
Top-line results from the Phase 2b ELPIS II trial in hypoplastic left heart syndrome (HLHS) are expected in mid-September following a planned database lock on August 31. Management emphasized FDA engagement and alignment on endpoints/SAP, and indicated a potential BLA pathway if data are supportive.
Read all positive updates
Company Guidance
The company reiterated near‑term guidance that the ELPIS II Phase 2b top‑line readout is expected in September (database lock planned for August 31), with primary efficacy assessed by objective measures including all‑cause mortality, cardiac transplant‑free survival, occurrence of cardiac transplantation and specified adverse cardiac events (and additional exploratory endpoints such as RVEF); some patients already have up to five years of follow‑up and a long‑term extension is planned up to 10 years. On the financial side, Q2 revenues were $0.3M (down $29k, or 10% year‑over‑year), G&A was $3.2M (up $600k, or 23%; ~$400k legal, $200k personnel), R&D was $3.2M (up $200k, or 7%), net loss was $6.1M (up $1.1M, or 22%), and cash & cash equivalents were $10.1M as of June 30, 2026, which the company expects will fund operations into Q4 2026 under the current budget. Other metrics highlighted: Laromestrocel is covered by 52 issued patents and >60 pending, holds five FDA expedited designations (including RMAT, Fast Track, orphan and rare pediatric disease), the PDCM IND became effective July 2025 enabling advancement to a Phase 2 registrational trial, and the Aging‑related Frailty data helped secure an XPRIZE HealthSpan Milestone 2 finalist award (selected from >600 applicants across 58 countries) with a $1M award (XPRIZE total $101M over 7 years; grand prize up to $81M).Longeveron Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19M | 1.20M | 2.39M | 709.00K | 1.22M | 1.31M |
| Gross Profit | 828.00K | 803.00K | 1.88M | 221.00K | 497.00K | 590.00K |
| EBITDA | -22.88M | -21.48M | -15.02M | -20.47M | -17.94M | -16.13M |
| Net Income | -23.47M | -22.70M | -15.97M | -21.41M | -18.84M | -17.05M |
Balance Sheet | ||||||
| Total Assets | 15.49M | 10.26M | 25.56M | 12.08M | 27.41M | 42.77M |
| Cash, Cash Equivalents and Short-Term Investments | 10.08M | 4.66M | 19.23M | 5.36M | 19.66M | 35.04M |
| Total Debt | 581.00K | 824.00K | 1.45M | 2.04M | 2.60M | 3.14M |
| Total Liabilities | 5.08M | 4.59M | 3.67M | 5.34M | 6.91M | 5.31M |
| Stockholders Equity | 10.40M | 5.67M | 21.89M | 6.74M | 20.50M | 37.45M |
Cash Flow | ||||||
| Free Cash Flow | -20.66M | -18.89M | -14.86M | -19.30M | -14.82M | -10.95M |
| Operating Cash Flow | -20.37M | -18.64M | -13.87M | -19.00M | -13.97M | -9.64M |
| Investing Cash Flow | -305.00K | -595.00K | -640.00K | 8.19M | -677.00K | -10.70M |
| Financing Cash Flow | 20.42M | 4.67M | 28.79M | 5.26M | -509.00K | 45.17M |
Longeveron Technical Analysis
Negative
0.68
Price Trends
6.89
Negative
7.51
Negative
7.21
Negative
Market Momentum
-0.15
Positive
42.95
Neutral
19.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 7.28, below the 50-day MA of 6.89, and below the 200-day MA of 7.21, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 42.95 is Neutral, neither overbought nor oversold. The STOCH value of 19.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGVN.
Longeveron Risk Analysis
Longeveron disclosed 91 risk factors in its most recent earnings report. Longeveron reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Longeveron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $19.93M | -2.63 | -70.81% | ― | ― | 56.99% | |
49 Neutral | $11.39M | -0.29 | -536.78% | ― | ― | 22.10% | |
48 Neutral | $6.03M | -0.36 | -394.24% | ― | ― | 90.37% | |
47 Neutral | $29.87M | -0.65 | -223.19% | ― | -42.74% | 20.66% | |
47 Neutral | $63.91M | -2.79 | -124.21% | ― | ― | -27.34% | |
46 Neutral | $79.11M | -3.87 | -47.92% | ― | -75.00% | 74.04% |
* Healthcare Sector Average
LGVN
Longeveron
6.58
-1.42
-17.75%
IBIO
Ibio
1.26
0.38
42.86%
EDSA
Edesa Biotech
4.72
2.28
93.44%
CMMB
Chemomab Therapeutics
2.69
-0.30
-10.03%
PCSA
Processa Pharmaceuticals
1.99
-2.80
-58.46%
FBLG
FibroBiologics, Inc.
1.76
-9.11
-83.81%
Longeveron Corporate Events
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Longeveron Executes 1-for-10 Reverse Stock Split
Neutral
Aug 24, 2026
On July 1, 2026, Longeveron’s stockholders approved a reverse stock split proposal for the company’s Class A and Class B common stock, with the board setting a final ratio of 1-for-10 on July 31, 2026. The reverse split became effectiv...
Business Operations and StrategyExecutive/Board Changes
Longeveron Appoints New Chief Financial Officer Jhaveri
Positive
Aug 19, 2026
On August 19, 2026, Longeveron announced the appointment of Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 17, 2026.Jhaveri, a veteran of biopharma and biotech finance wi...
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Longeveron Restores Nasdaq Compliance with New Audit Committee
Positive
Jul 29, 2026
In March 2026, Longeveron temporarily fell out of compliance with Nasdaq rules requiring its audit committee to have at least three independent directors, including one audit committee financial expert, following the resignation of a board member....
Business Operations and StrategyExecutive/Board Changes
Longeveron Enhances CEO Compensation and Retention Protections
Positive
Jul 15, 2026
On July 8, 2026, Longeveron Inc. entered into a revised employment letter agreement with Chief Executive Officer Stephen Willard, removing a prior deferral on his $500,000 annual base salary and formalizing eligibility for an annual cash bonus tar...
Business Operations and StrategyExecutive/Board Changes
Longeveron grants special equity awards to Executive Chairman
Positive
Jul 8, 2026
On July 6, 2026, Longeveron, Inc. granted special equity awards to its Executive Chairman under the company’s amended 2021 Incentive Award Plan, recognizing his significant role in completing the March 2026 financing transaction and securing...
Business Operations and StrategyExecutive/Board Changes
Longeveron strengthens financial leadership with new CFO appointment
Positive
Jul 6, 2026
Longeveron Inc., a clinical-stage biotech focused on stem cell-based regenerative therapies for rare pediatric and aging-related conditions, is advancing its lead mesenchymal stem cell candidate laromestrocel (Lomecel-B) across multiple indication...
Executive/Board Changes
Longeveron Announces CFO Transition to Internal Successor
Positive
Jun 5, 2026
On June 1, 2026, Longeveron Inc. announced that Chief Financial Officer Lisa Locklear will step down effective July 10, 2026, as she pursues board roles and other professional and personal interests. The company said her departure does not stem fr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.